Kathryn M. McNeil
Plus aucun poste en cours
Profil
Kathryn M.
McNeil worked as Head-Investor & Media Relations at Chelsea Therapeutics International Ltd.
from 2009 to 2012.
She was also VP-Investor Relations & Public Relations at Novelos Therapeutics, Inc. from 2013 to 2014, and VP-Investor Relations & Corporate Communications at Cellectar Biosciences, Inc. from 2013 to 2015.
In 2017, she worked as Head-Communication & Investor Relations at Invitae Corp.
Ms. McNeil obtained an undergraduate degree from Wesleyan University.
Anciens postes connus de Kathryn M. McNeil
| Sociétés | Poste | Fin |
|---|---|---|
| INVITAE CORPORATION | Public Communications Contact | 01/04/2018 |
| CELLECTAR BIOSCIENCES, INC. | Investor Relations Contact | 28/07/2015 |
Novelos Therapeutics, Inc.
 Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Investor Relations Contact | 12/02/2014 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Investor Relations Contact | - |
Formation de Kathryn M. McNeil
| Wesleyan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| INVITAE CORPORATION | Health Services |
| CELLECTAR BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Chelsea Therapeutics International Ltd.
 Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
